Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up

被引:21
|
作者
Hajili, Turkan [1 ]
Ohlmann, Carsten H. [1 ]
Linxweiler, Johannes [1 ]
Niklas, Christina [1 ]
Janssen, Martin [1 ]
Siemer, Stefan [1 ]
Stoeckle, Michael [1 ]
Saar, Matthias [1 ]
机构
[1] Saarland Univ, Dept Urol & Pediat Urol, D-66421 Homburg, Germany
关键词
inductive androgen deprivation; inoperable high-risk prostate cancer; prostate-specific antigen nadir; radical prostatectomy; #pcsm; #ProstateCancer; NEOADJUVANT HORMONAL-THERAPY; HIGH-RISK; PHASE-II; MEN; SURVIVAL; ADENOCARCINOMA;
D O I
10.1111/bju.14393
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesTo determine the outcomes of complete surgical resection of T4 prostate cancer after inductive androgen-deprivation therapy (ADT), as inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet. Patients and MethodsA monocentric RP database was queried for patients initially diagnosed with T4 prostate cancer, considered primarily as inoperable because of a fixed mass defined by rectal examination in combination with high PSA level and/or large foci of biopsy confirmed undifferentiated prostate cancer. Treatment consisted of primary ADT until PSA nadir with consecutive RP. Patients underwent retropubic RP (RRP) or robot-assisted laparoscopic RP (RALP) after inductive ADT until achievement of the PSA nadir, which is in general reached after 6-7months. The intraoperative course and complications were analysed. Finally, Kaplan-Meier estimates were calculated for overall survival (OS) and prostate cancer-specific survival (PCSS). ResultsWe retrospectively identified 116 patients treated between 2000 and 2014. At diagnosis, the median (range) PSA level was 37.6 (2.44-284) ng/mL. The preoperative median (range) PSA after inductive ADT was 0.73 (0.01-34) ng/mL. Thereafter, patients underwent RRP or, since 2006, RALP. The median (95% confidence interval) OS was 156 (118.9-193.1) months. The PCSS at 150months was 82%. ConclusionsSurgical therapy of primarily inoperable prostate cancer is feasible and safe after inductive ADT. The OS of this cohort seems comparable with results described for patients with primary operable high-risk prostate cancer.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 50 条
  • [41] Re: Long-Term Follow-up of a Randomized Trial of Radiation with or without Androgen Deprivation Therapy for Localized Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2016, 195 (05): : 1471 - 1472
  • [42] Long-term oncologic outcomes after radical prostatectomy in clinically localized prostate cancer: 10-year follow-up in Korea
    Suh, Jungyo
    Jung, Jae Hyun
    Jeong, Chorok
    Lee, Sang Eun
    Lee, Eunsik
    Ku, Ja Hyeon
    Kim, Hyeon Hoe
    Kwak, Cheol
    INVESTIGATIVE AND CLINICAL UROLOGY, 2020, 61 (03) : 269 - 276
  • [43] Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
    Yuzuri Tsurumaki Sato
    Hiroshi Fukuhara
    Motofumi Suzuki
    Tetsuya Fujimura
    Tohru Nakagawa
    Hiroaki Nishimatsu
    Haruki Kume
    Teppei Morikawa
    Masashi Fukayama
    Yukio Homma
    BMC Urology, 14
  • [44] Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
    Sato, Yuzuri Tsurumaki
    Fukuhara, Hiroshi
    Suzuki, Motofumi
    Fujimura, Tetsuya
    Nakagawa, Tohru
    Nishimatsu, Hiroaki
    Kume, Haruki
    Morikawa, Teppei
    Fukayama, Masashi
    Homma, Yukio
    BMC UROLOGY, 2014, 14
  • [45] Intermittent androgen deprivation for biologic recurrence after radical prostatectomy:: Long-term experience
    Peyromaure, M
    Delongchamps, NB
    Debré, B
    Zerbib, M
    UROLOGY, 2005, 65 (04) : 724 - 729
  • [46] The effect of neoadjuvant androgen deprivation therapy on long-term outcome after radical prostatectomy
    Ondracek, Rochelle D. Payne
    Hayn, Matthew H.
    Poch, Michael A.
    Ray, Michael J.
    Davis, Warren
    Curtis, Alexandra
    Kim, Hyung L.
    Morrison, Carl D.
    Marshall, James R.
    Mohler, James L.
    CANCER RESEARCH, 2011, 71
  • [47] Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?
    Taguchi, Satoru
    Fukuhara, Hiroshi
    Morikawa, Teppei
    Matsumoto, Akihiko
    Miyazaki, Hideyo
    Nakagawa, Tohru
    Fujimura, Tetsuya
    Kume, Haruki
    Igawa, Yasuhiko
    Homma, Yukio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (12) : 1143 - 1147
  • [48] HIGH FAILURE RATE ASSOCIATED WITH LONG-TERM FOLLOW-UP OF NEOADJUVANT ANDROGEN DEPRIVATION FOLLOWED BY RADICAL PROSTATECTOMY FOR STAGE-C PROSTATIC-CANCER
    CHER, ML
    SHINOHARA, K
    BRESLIN, S
    VAPNEK, J
    CARROLL, PR
    BRITISH JOURNAL OF UROLOGY, 1995, 75 (06): : 771 - 777
  • [49] LONG-TERM RESULTS OF RADICAL PROSTATECTOMY - 15-YEAR FOLLOW-UP OF 100 PATIENTS
    FROHMULLER, HGW
    THEISS, M
    EUROPEAN UROLOGY, 1995, 27 : 41 - 44
  • [50] OUTCOMES OF SALVAGE LYMPH NODE DISSECTION FOR OLIGMETASTATIC RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: RESULTS OF A SINGLE-INSTITUTION MULTIDISCIPLINARY TEAM SERIES
    Patel, Amit
    Rhee, H.
    Heathcote, P.
    Lawson, M.
    Preston, J.
    Vela, I.
    Pryor, D.
    Lehman, M.
    Wood, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 38 - 38